打开APP

基因泰克与NewLink签订癌症免疫疗法合作协议

  1. IDO通路
  2. 免疫疗法
  3. 基因泰克
  4. 癌症

来源:生物谷 2014-10-23 10:31

直以来,基因泰克都以其旺盛的精力而闻名于生物医药产业领域。不久前,在对抗西非埃博拉疫情的战役中,基因泰克就不断加速进行其埃博拉病毒疫苗的研究而受到业界的广泛关注。而现在,基因泰克公司又有新动作。

2014年10月23日讯 /生物谷BIOON/ --一直以来,基因泰克都以其旺盛的精力而闻名于生物医药产业领域。不久前,在对抗西非埃博拉疫情的战役中,基因泰克就不断加速进行其埃博拉病毒疫苗的研究而受到业界的广泛关注。而现在,基因泰克公司又有新动作。

最近公司宣布将与爱荷华州的生物技术公司NewLink公司合作进行癌症免疫疗法NLG919的早期研究。基因泰克希望通过与NewLink基因公司的合作将NLG919与罗氏开发的PD-L1药物结合起来。据公司透露,此次协议的金额将高达10亿美元之多。其中包括了一亿五千万美元的预付金和高达十亿美元的里程碑基金。除此之外,基因泰克公司还将对NewLink公司提供研究方面的技术支持和人力支持。基因泰克对这一协议的重视程度可见一斑。

根据协议,NewLink公司将向基因泰克公司提供其开发的NLG919药物分子,这是一种IDO通路移植物。NewLink公司的研究人员认为IDO通路能够作为DP-1和PD-L1检验点抑制剂的替代者。通过阻断IDO通路,科学家就有可能使癌细胞无法再逃脱人体免疫系统的清除机制而被清除。而基因泰克公司也希望通过这次合作,找到将NLG919整合加入联合免疫疗法的途径。

作为制药巨头罗氏公司的子公司,基因泰克具有世界上最富有创造力的研究团队。这也是公司为什么一直以来都很少寻求研发合作的原因。然而今年以来,基因泰克的研究策略似乎有所转变。公司在今年早些时候收购了Seragon Pharmaceuticals公司。(生物谷Bioon.com)

详细英文报道:

Biotech powerhouse Genentech is going all in with Ames, IA-based NewLink Genetics, partnering on an early-stage cancer program which has been billed as an important example of a new class of checkpoint inhibitors. And Genentech says that it plans to build a portfolio of programs pairing this therapeutic with Roche's closely watched PD-L1 drug.

NewLink has been gaining a considerable amount of attention--both plaudits and pans--during the recent Ebola scare, advancing a vaccine that the company believes has potential in stopping the deadly West African epidemic. But this morning the market's attention shifted to cancer as NewLink outlined a rich $1 billion-plus pact. The smaller biotech is getting a hefty $150 million upfront along with more than $1 billion in potential milestones.

NewLink shares ($NLNK) shot up 30% this morning.

Genentech, a leader in the cancer field that will now share its considerable prestige with NewLink, was drawn by NLG919, an IDO pathway inhibitor. According to NewLink, the IDO pathway acts as an alternative to the PD-1 and PD-L1 checkpoint inhibitors, blocking an escape path that cancer cells use to steer clear of an immune system response. And Genentech will now explore how new combinations using NLG919 can be used to fight cancer.

In addition to the upfront and milestones, Genentech is funding R&D and manufacturing as well as providing research support directly to the company. NewLink is also hanging on to "certain" U.S. copromotion rights as well as the right to proceed with new in-house combos that match IDO inhibitors with TDO inhibitors.

The deal marks another departure for Genentech from its traditionally low-key presence in the biotech deal-making field. Up until this year, the Roche subsidiary has executed only rare industry pacts, convinced that its own pipeline offers an abundance of new products and pairing opportunities. This year, though, Genentech also bought Seragon Pharmaceuticals in a rare $1.7 billion acquisition deal. And partnering chief James Sabry, once content with small add-on programs, appears to have raised his sights considerably in terms of total deal values.

This also isn't Genentech's first trip down the IDO pathway. Last summer Genentech followed Bristol-Myers and others which have partnered with Incyte, pairing its anti-PD-L1 drug MPDL3280A with the biotech's closely-watched IDO1 inhibitor, INCB24360.

"We are intrigued by the biology of the IDO and TDO compounds and are very interested in the potential to combine them with Genentech's portfolio of novel therapies," said Sabry in a statement. "We are delighted to have initiated this significant partnership with NewLink. We hope this collaboration will lead to new therapies for people with cancer."

 

版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体、网站或个人不得转载,否则将追究法律责任。取得书面授权转载时,须注明“来源:生物谷”。其它来源的文章系转载文章,本网所有转载文章系出于传递更多信息之目的,转载内容不代表本站立场。不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。

87%用户都在用生物谷APP 随时阅读、评论、分享交流 请扫描二维码下载->